Johnson & Johnson (NYSE:JNJ) is poised to announce new data related to its Ad26 COVID-19 vaccine early next week.
In an earnings call yesterday, management hinted that they expect results from the vaccine to be positive but stopped short at revealing details.
“We think it’s very important to follow the data — to follow the science,” said JNJ CEO Alex Gorsky after declining to answer a question related to COVID-19 variants and vaccine efficacy until the official data announcement.
[Related: Johnson & Johnson pharma sales drive Street-beating Q4 results]
If the company’s adenovirus-based vaccine performs in the same league as those from Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE), Ad26 could play a vital role in stemming the COVID-19 crisis. Unlike competitors’ vaccines, Ad26 could be offered in a single dose, potentially simplifying mass-vaccination efforts.
Former Operation Warp Speed chief Moncef Slaoui suggested that Ad26 vaccine…